Small molecule inhibitors of ercc1-xpf protein-protein interaction synergize alkylating agents in cancer cellss

Molecular Pharmacology

Volumn 84, Issue 1, 2013, Pages 12-24

  Jordheim, Lars Petter ^a   Barakat, Khaled H ^a,b,c   Heinrich Balard, Laurence ^a,d   Matera, Eva Laure ^a   Cros Perrial, Emeline ^a   Bouledrak, Karima ^a   Sabeh, Rana El ^a   Perez Pineiro, Rolando ^a,b   Wishart, David S ^a   Cohen, Richard ^a,d,e   Tuszynski, Jack ^a,b   Dumontet, Charles ^a,b  

^a CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^b UNIVERSITY OF ALBERTA   (Canada)

^c FAYOUM UNIVERSITY   (Egypt)

^d UNIVERSITÉ DE LYON   (France)

^e EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; HISTONE H2AX; MITOMYCIN; OLAPARIB; PROTEIN; UNCLASSIFIED DRUG; XPF PROTEIN;

ARTICLE; CANCER CELL; COMPUTER MODEL; CONTROLLED STUDY; CYTOTOXICITY; DNA REPAIR; DRUG POTENTIATION; DRUG SCREENING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; ULTRAVIOLET C RADIATION;

ANTINEOPLASTIC AGENTS, ALKYLATING; CELL LINE, TUMOR; CISPLATIN; DNA BREAKS, DOUBLE-STRANDED; DNA REPAIR; DNA-BINDING PROTEINS; DRUG SYNERGISM; ENDONUCLEASES; HCT116 CELLS; HISTONES; HUMANS; MITOMYCIN; MOLECULAR DOCKING SIMULATION; NEOPLASMS; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; SMALL MOLECULE LIBRARIES;

EID: 84879089076     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.112.082347     Document Type: Article

References (40)

1. Amaro RE, Baron R, and McCammon JA (2008) An improved relaxed complex scheme for receptor flexibility in computer-Aided drug design. J Comput Aided Mol Des 22:693-705.
2. Arora S, Kothandapani A, Tillison K, Kalman-Maltese V, and Patrick SM (2010) Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells. DNA Repair (Amst) 9:745-753.
3. Azmi AS and Mohammad RM (2009) Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy. J Cell Physiol 218:13-21.
4. Barakat K, Mane J, Friesen D, and Tuszynski J (2010) Ensemble-based virtual screening reveals dual-inhibitors for the p53-MDM2/MDMX interactions. J Mol Graph Model 28:555-568
5. Barakat K and Tuszynski J (2011) Relaxed complex scheme suggests novel inhibitors for the lyase activity of DNA polymerase beta. J Mol Graph Model 29:702-716.
6. Barakat KH, Jordheim LP, Perez-Pineiro R, Wishart D, Dumontet C, and Tuszynski JA (2012) Virtual screening and biological evaluation of inhibitors targeting the XPA-ERCC1 interaction. PLoS ONE 7:e51329.
7. Barakat KH, Torin Huzil J, Luchko T, Jordheim L, Dumontet C, and Tuszynski J (2009) Characterization of an inhibitory dynamic pharmacophore for the ERCC1-XPA interaction using a combined molecular dynamics and virtual screening approach. J Mol Graph Model 28:113-130.
8. Case DA, Cheatham T, Darden T, Gohlke H, Luo R, Merz KM Jr., Onufriev A, Simmerling C, Wang B, and Woods R (2005) The Amber biomolecular simulation programs. J Comput Chem 26:1668-1688
9. Chou TC and Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55.
10. Coste I, Le Corf K, Kfoury A, Hmitou I, Druillennec S, Hainaut P, Eychene A, Lebecque S, and Renno T (2010) Dual function of MyD88 in RAS signaling and inflammation, leading to mouse and human cell transformation. J Clin Invest 120:3663-3667.
11. Damia G, Tagliabue G, Zucchetti M, Davoli E, Sessa C, Cavalli F, and D'Incalci M (1992) Activity of aphidicolin glycinate alone or in combination with cisplatin in a murine ovarian tumor resistant to cisplatin. Cancer Chemother Pharmacol 30: 459-464.
12. Dolinsky TJ, Czodrowski P, Li H, Nielsen JE, Jensen JH, Klebe G, and Baker NA (2007) PDB2PQR: expanding and upgrading automated preparation of biomolecular structures for molecular simulations. Nucleic Acids Res 35 (Web Server issue):W522-5.
13. Frostell-Karlsson A, Remaeus A, Roos H, Andersson K, Borg P, Hämäläinen M, and Karlsson R (2000) Biosensor analysis of the interaction between immobilized human serum albumin and drug compounds for prediction of human serum albumin binding levels. J Med Chem 43:1986-1992.
14. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M, and Kroemer G (2012) Molecular mechanisms of cisplatin resistance. Oncogene 31: 1869-1883.
15. Gasteiger J and Marsili M (1980) Iterative partial equalization of orbital electronegativity: a rapid access to atomic charges. Tetrahedron 36:3219-3228
16. Hsu DS, Lan HY, Huang CH, Tai SK, Chang SY, Tsai TL, Chang CC, Tzeng CH, Wu KJ, and Kao JY et al. (2010) Regulation of excision repair cross-complementation group 1 by Snail contributes to cisplatin resistance in head and neck cancer. Clin Cancer Res 16:4561-4571.
17. Hubner RA, Riley RD, Billingham LJ, and Popat S (2011) Excision repair crosscomplementation group 1 (ERCC1) status and lung cancer outcomes: a metaanalysis of published studies and recommendations. PLoS ONE 6:e25164.
18. Jamieson ER and Lippard SJ (1999) Structure, Recognition, and Processing of Cisplatin-DNA Adducts. Chem Rev 99:2467-2498
19. Jordheim LP, Guittet O, Lepoivre M, Galmarini CM, and Dumontet C (2005) Increased expression of the large subunit of ribonucleotide reductase is involved in resistance to gemcitabine in human mammary adenocarcinoma cells. Mol Cancer Ther 4:1268-1276.
20. Kale L, Skeel R, Bhandarkar M, Brunner R, Gursoy A, Krawetz N, Phillips J, Shinozaki A, Varadarajan K, and Schulten K (1999) NAMD2: Greater Scalability for Parallel Molecular Dynamics. J Comput Phys 151:283-312.
21. Kollman PA, Massova I, Reyes C, Kuhn B, Huo S, Chong L, Lee M, Lee T, Duan Y, and Wang W et al. (2000) Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Acc Chem Res 33:889-897.
22. Kuhn B, Gerber P, Schulz-Gasch T, and Stahl M (2005) Validation and use of the MM-PBSA approach for drug discovery. J Med Chem 48:4040-4048
23. Lakowicz JR(1999) Principles of fluorescence spectroscopy, Second ed. Kluwer Academic/Plenum, New York. Lin JH, Perryman AL, Schames JR, and McCammon JA (2002) Computational drug design accommodating receptor flexibility: the relaxed complex scheme. J Am Chem Soc 124:5632-5633.
24. McHugh PJ, Spanswick VJ, and Hartley JA (2001) Repair of DNA interstrand crosslinks: molecular mechanisms and clinical relevance. Lancet Oncol 2:483-490.
25. McNeil EM and Melton DW (2012) DNA repair endonuclease ERCC1-XPF as a novel therapeutic target to overcome chemoresistance in cancer therapy. Nucleic Acids Res 40:9990-10004.
26. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, and Olson AJ (1998) Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem 19:1639-1662.
27. Niedernhofer LJ, Odijk H, Budzowska M, van Drunen E, Maas A, Theil AF, de Wit J, Jaspers NG, Beverloo HB, and Hoeijmakers JH et al. (2004) The structure-specific endonuclease Ercc1-Xpf is required to resolve DNA interstrand cross-link-induced double-strand breaks. Mol Cell Biol 24:5776-5787.
28. Nouspikel T (2009) DNA repair in mammalian cells : Nucleotide excision repair: variations on versatility. Cell Mol Life Sci 66:994-1009.
29. O'Dwyer PJ, Moyer JD, Suffness M, Harrison SD, Jr., Cysyk R, Hamilton TC, and Plowman J (1994) Antitumor activity and biochemical effects of aphidicolin glycinate (NSC 303812) alone and in combination with cisplatin in vivo. Cancer Res 54:724-729.
30. Olive PL and Banáth JP (2009) Kinetics of H2AX phosphorylation after exposure to cisplatin. Cytometry B Clin Cytom 76:79-90.
31. Phillips JC, Braun R, Wang W, Gumbart J, Tajkhorshid E, Villa E, Chipot C, Skeel RD, Kale L, and Schulten K (2005) Scalable molecular dynamics with NAMD. J Comput Chem 26:1781-1802.
32. Rahn JJ, Adair GM, and Nairn RS (2010) Multiple roles of ERCC1-XPF in mammalian interstrand crosslink repair. Environ Mol Mutagen 51:567-581.
33. Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E, Nygren AO, Zander SA, Derksen PW, de Bruin M, Zevenhoven J, and Lau A et al. (2008) High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci USA 105: 17079-17084.
34. Shangary S and Wang S (2008) Targeting the MDM2-p53 interaction for cancer therapy. Clin Cancer Res 14:5318-5324.
35. Shao J, Tanner SW, Thompson N, and Cheatham TE, 3rd (2007) Clustering Molecular Dynamics Trajectories: 1. Characterizing the Performance of Different Clustering Algorithms. J Chem Theory Comput 3:2312-2334.
36. Tripsianes K, Folkers G, Ab E, Das D, Odijk H, Jaspers NG, Hoeijmakers JH, Kaptein R, and Boelens R (2005) The structure of the human ERCC1/XPF interaction domains reveals a complementary role for the two proteins in nucleotide excision repair. Structure 13:1849-1858
37. Tsodikov OV, Ivanov D, Orelli B, Staresincic L, Shoshani I, Oberman R, Schärer OD, Wagner G, and Ellenberger T (2007) Structural basis for the recruitment of ERCC1-XPF to nucleotide excision repair complexes by XPA. EMBO J 26: 4768-4776.
38. Usanova S, Piée-Staffa A, Sied U, Thomale J, Schneider A, Kaina B, and Köberle B (2010) Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression. Mol Cancer 9: 248van de Weert M and Stell L (2011) Fluorescence quenching and ligand binding: A critical discussion of a popular methodology. J Mol Struct 998:144-150.
39. Wood RD (2010) Mammalian nucleotide excision repair proteins and interstrand crosslink repair. Environ Mol Mutagen 51:520-526.
40. Youn CK, Kim MH, Cho HJ, Kim HB, Chang IY, Chung MH, and You HJ (2004) Oncogenic H-Ras up-regulates expression of ERCC1 to protect cells from platinumbased anticancer agents. Cancer Res 64:4849-4857.